<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548051" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548051/" /><meta name="ncbi_pagename" content="Emergency Contraceptive Agents - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Emergency Contraceptive Agents - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Emergency Contraceptive Agents" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2020/06/02" /><meta name="citation_pmid" content="31643382" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548051/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Emergency Contraceptive Agents" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2020/06/02" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548051/" /><meta name="description" content="Levonorgestrel is a synthetic progesterone that is used for emergency contraception. Levonorgestrel is also used alone and in combination with estrogens in conventional oral contraceptives. Use of levonorgestrel for emergency contraception has not been associated with serum enzyme elevations or clinically apparent liver injury with jaundice." /><meta name="og:title" content="Emergency Contraceptive Agents" /><meta name="og:type" content="book" /><meta name="og:description" content="Levonorgestrel is a synthetic progesterone that is used for emergency contraception. Levonorgestrel is also used alone and in combination with estrogens in conventional oral contraceptives. Use of levonorgestrel for emergency contraception has not been associated with serum enzyme elevations or clinically apparent liver injury with jaundice." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548051/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/EmergencyContracepti/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548051/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8C34460465EBA10000000007720205.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548051_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548051_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Emapalumab/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Emicizumab/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548051_"><span class="title" itemprop="name">Emergency Contraceptive Agents</span></h1><p class="small">Last Update: <span itemprop="dateModified">June 2, 2020</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="EmergencyContracepti.OVERVIEW"><h2 id="_EmergencyContracepti_OVERVIEW_">OVERVIEW</h2><p>Oral means of emergency contraception, colloquially known as &#x0201c;morning after&#x0201d; pills, are used to prevent unwanted pregnancy after unprotected intercourse or suspected contraceptive failure. Two commonly used forms of emergency contraception are levonorgestrel and ulipristal acetate. Both can be administered as a single oral dose, ulipristal within 5 days and levonorgestrel within 2 days of the unprotected intercourse. Both have been shown to be safe and effective, rates of subsequent pregnancy being 0.6% to 3% compared to an expected rate of 5% to 6%. Levonorgestrel is available over-the-counter whereas ulipristal, at least in the United States, is available by prescription only. Neither approach to emergency contraception has been linked to serum enzyme elevations or to clinically apparent liver injury. However, ulipristal when given in daily doses in 3 month courses as therapy for symptomatic uterine fibroids has been linked to several instances of clinically apparent liver injury, some of which have been severe and even fatal.</p><div id="EmergencyContracepti.Levonorgestrel"><h3>Levonorgestrel</h3><div id="EmergencyContracepti.Introduction"><h4>Introduction</h4><p>Levonorgestrel is a synthetic progesterone that is used for emergency contraception. Levonorgestrel is also used alone and in combination with estrogens in conventional oral contraceptives. Use of levonorgestrel for emergency contraception has not been associated with serum enzyme elevations or clinically apparent liver injury with jaundice.</p></div><div id="EmergencyContracepti.Background"><h4>Background</h4><p>Levonorgestrel (lee" voe nor jes' trel) is a synthetic progesterone that is used as a single or as two oral doses within 2 days of unprotected intercourse or contraceptive failure as a means of emergency contraception. Levonorgestrel acts as an agonist of the progesterone receptor and is believed to act by preventing ovulation. In both animal models and in human trials, levonorgestrel appears to be effective only when given before the luteinizing hormone (LH) surge that precedes ovulation and has little or no effect on fertilization or implantation. In large prospective studies, levonorgestrel given in a single or as two doses 12 hours apart lowered the rate of unwanted pregnancies by 50% to 90% of the expected rate, and the effect was seen for as long as 48 hours after unprotected intercourse or suspected contraceptive failure. The overall failure rates of levonorgestrel have ranged from 0.6% to 3.1%, the expected rates being 5% to 6%. Levonorgestrel was approved in the United States for use as emergency contraception in 1982 and remains available generically and over-the-counter as tablets of 0.75 and 1.5 mg. The recommended regimen is a total dose of 1.5 mg within 72 hours of the unprotected intercourse or suspected contraceptive failure, given either as a single or split (12 hours apart) oral dose. Side effects are generally mild-to-moderate in severity and can include headache, nausea, abdominal pain, dysmenorrhea, breast tenderness, fatigue, and dizziness.</p><p>Levonorgestrel is also used as a progestin in conventional oral contraceptives, administered alone or in combination with estrogens. The safety and hepatotoxicity of oral contraceptives are discussed separately in LiverTox in sections Estrogens and Oral Contraceptives, and Progesterone and the Progestins.</p></div><div id="EmergencyContracepti.Hepatotoxicity"><h4>Hepatotoxicity</h4><p>In large prospective trials of levonorgestrel as emergency contraception that included laboratory testing, mean serum <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> and <a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a> levels remained unchanged and only rare, minor elevations of serum enzymes occurred that were invariably transient, not accompanied by jaundice or symptoms and not considered related to the emergency contraception. Despite widescale use of levonorgestrel for several decades, there have been no published reports of hepatotoxicity attributable to its use as emergency contraception.</p><p>Likelihood score: E (unlikely cause of clinically apparent liver injury).</p></div><div id="EmergencyContracepti.Mechanism_of_Injury"><h4>Mechanism of Injury</h4><p>The mechanism by which levonorgestrel used for emergency contraception might cause liver injury is uncertain. It is typically given in one or two low doses, the total amount being only 1.5 mg. Levonorgestrel is metabolized in the liver predominantly via CYP 3A4 and is susceptible to drug-drug interactions with potent inducers or inhibitors of the drug-metabolizing enzyme. Levonorgestrel is a progesterone, but has not been linked to the cholestatic forms of injury associated with convention oral contraceptives that contain progesterone alone or combined with estrogens.</p></div></div><div id="EmergencyContracepti.Ulipristal"><h3>Ulipristal</h3><div id="EmergencyContracepti.Introduction_1"><h4>Introduction</h4><p>Ulipristal acetate is a selective progesterone receptor modulator that is used in a single oral dose for emergency contraception. Use of ulipristal has not been associated with serum enzyme elevations or with clinically apparent liver injury with jaundice.</p></div><div id="EmergencyContracepti.Background_1"><h4>Background</h4><p>Ulipristal (ue" le pris' tal) is a selective progesterone receptor modulator that is used in a single oral dose within 5 days of unprotected intercourse or suspected contraceptive failure as a means of emergency contraception. Ulipristal acts as a mixed, partial agonist and antagonist of the progesterone receptor and is believed to act by preventing both ovulation and fertilization. Unlike levonorgestrel, ulipristal can be used up to 5 days after the episode of unprotected intercourse, being effective both before and during the early phase of the luteinizing hormone (LH) surge. Ulipristal has minor effects on the uterine epithelium that may inhibit implantation. In large prospective studies, ulipristal was found to lower the rate of unwanted pregnancies by 50% to 90% of the expected rate when given up to 5 days after unprotected intercourse or suspected contraceptive failure. The overall failure rate of emergency contraception with ulipristal has ranged from 0.9% to 2.1%, the expected rates being in the range of 5% to 6%. Ulipristal was approved in the United States for use in emergency contraception in 2010 and remains available by prescription as tablets of 30 mg under the brand name Ella. The recommended regimen is a single oral dose of 30 mg within 5 days of the unprotected intercourse or suspected contraceptive failure. Side effects are generally mild-to-moderate in severity and can include headache, nausea, abdominal pain, dysmenorrhea, breast tenderness, fatigue, and dizziness.</p><p>Ulipristal has also been evaluated as nonsurgical therapy of uterine fibroids. When given in daily doses of 5 to 10 mg for 2 to 3 months, ulipristal was found to decrease uterine bleeding and total fibroid volume. Side effects included amenorrhea, headaches, hot flushes, nausea, vomiting, abdominal cramps and menorrhagia. Ulipristal was approved for this indication in the European Union, but its use was restricted after several reports of severe liver injury were reported in women being treated for uterine fibroids.</p></div><div id="EmergencyContracepti.Hepatotoxicity_1"><h4>Hepatotoxicity</h4><p>In large prospective trials of ulipristal that included laboratory testing, there were isolated moderate elevations in <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> levels, but all were transient, less than 3 times the upper limit of normal and not accompanied by jaundice or symptoms. Since approval of ulipristal in 2010 there have been no reports of liver injury associated with its use in emergency contraception as a one-time dose.</p><p>Likelihood score when used for emergency contraception: E (unlikely cause of clinically apparent liver injury).</p><p>Ulipristal has also been used in daily doses of 5 mg in 3 month courses as therapy of uterine fibroids. In preregistration trials, ulipristal when given in doses of 5 mg daily was not associated with serum enzyme elevations or with instances of clinically apparent liver injury. Ulipristal did not receive approval as therapy of uterine fibroids in the United States but was approved for this indication in the European Union in 2012. Subsequently, there have been several reports of severe liver injury, including acute liver failure requiring liver transplantation in women being treated for fibroids. The latency to onset ranged from 1 to 6 months and the clinical presentation was with fatigue and an acute hepatocellular pattern of enzyme elevations followed by jaundice. Several instances of acute liver failure were reported to the European Medicines Agency which conducted a formal review of the hepatotoxicity of ulipristal in 2018, which led to a restriction in its use to moderately-to-severely symptomatic uterine fibroids unresponsive to other therapies. Avoidance of therapy in patients with preexisting liver disease and monthly monitoring for serum enzyme elevations was also recommended, with prompt discontinuation for de novo elevations. Whether prospective monitoring is effective in preventing serious liver injury in women treated with ulipristal is unclear. Similar cases of clinically apparent liver injury have not been reported with the use of ulipristal as an emergency contraceptive agent.</p><p>Likelihood score when used in daily doses for uterine fibroids: C (probable cause of clinically apparent liver injury).</p></div><div id="EmergencyContracepti.Mechanism_of_Injury_1"><h4>Mechanism of Injury</h4><p>The mechanism by which ulipristal might cause liver injury is uncertain. It is typically given as a single dose for emergency contraception, but in daily somewhat low doses for symptomatic uterine fibroids. Ulipristal is metabolized in the liver predominantly via CYP 3A4 and is susceptible to drug-drug interactions with potent inducers or inhibitors of CYP 3A. Ulipristal is a partial progesterone receptor agonist, but has not been linked to the cholestatic forms of injury associated with estrogen and progesterone administration. The hepatocellular injury associated with long term use appears to be idiosyncratic.</p><p>Drug Class: Obstetrical and Gynecological Agents, Emergency Contraceptive Agents</p></div></div></div><div id="EmergencyContracepti.PRODUCT_INFORMATION"><h2 id="_EmergencyContracepti_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Levonorgestrel &#x02013; Generic, Plan B&#x000ae;</p><p>Ulipristal Acetate &#x02013; Ella&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Emergency Contraceptive Agents</p><p><u>COMPLETE LABELING</u></p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Levonorgestrel" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Levonorgestrel</a></p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=ULIPRISTAL+ACETATE&#x00026;pagesize=20&#x00026;page=1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Ulipristal Acetate</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="EmergencyContracepti.CHEMICAL_FORMULAS_A"><h2 id="_EmergencyContracepti_CHEMICAL_FORMULAS_A_">CHEMICAL FORMULAS AND STRUCTURES</h2><div id="EmergencyContracepti.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548051/table/EmergencyContracepti.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__EmergencyContracepti.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_EmergencyContracepti.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_EmergencyContracepti.Tc_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NO</th><th id="hd_h_EmergencyContracepti.Tc_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_EmergencyContracepti.Tc_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_EmergencyContracepti.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Levonorgestrel</td><td headers="hd_h_EmergencyContracepti.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134976459" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">797-63-7</a></td><td headers="hd_h_EmergencyContracepti.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C21-H28-O2</td><td headers="hd_h_EmergencyContracepti.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134976459" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=134976459" alt="image 134976459 in the ncbi pubchem database" /></a></td></tr><tr><td headers="hd_h_EmergencyContracepti.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ulipristal</td><td headers="hd_h_EmergencyContracepti.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135271930" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">159811-51-5</a></td><td headers="hd_h_EmergencyContracepti.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C28-H35-N-O3</td><td headers="hd_h_EmergencyContracepti.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135271930" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=135271930" alt="image 135271930 in the ncbi pubchem database" /></a></td></tr><tr><td headers="hd_h_EmergencyContracepti.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Progesterone</td><td headers="hd_h_EmergencyContracepti.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134971194" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">57-83-0</a></td><td headers="hd_h_EmergencyContracepti.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C21-H30-O2</td><td headers="hd_h_EmergencyContracepti.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134971194" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=134971194" alt="image 134971194 in the ncbi pubchem database" /></a></td></tr></tbody></table></div></div></div><div id="EmergencyContracepti.ANNOTATED_BIBLIOGRA"><h2 id="_EmergencyContracepti_ANNOTATED_BIBLIOGRA_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 02 June 2020</p><ul class="first-line-outdent"><li><div class="bk_ref" id="EmergencyContracepti.REF.zimmerman.1999">Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999.<div><i>(Review of hepatotoxicity published in 1999; does not specifically discuss levonorgestrel or ulipristal).</i></div></div></li><li><div class="bk_ref" id="EmergencyContracepti.REF.chitturi.2013">Chitturi S, Farrell GC. Estrogen receptor antagonists. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 610-2.<div><i>(Review of hepatotoxicity of hormonal agents; discusses estrogens and progestins, but does not specifically discuss levonorgestrel or ulipristal).</i></div></div></li><li><div class="bk_ref" id="EmergencyContracepti.REF.schimmer.2011">Schimmer BP, Parker KL. Contraception and pharmacotherapy of obstetrical and gynecological disorders. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 1833-52.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="EmergencyContracepti.REF4">Emergency contraception OTC. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2004;<span class="ref-vol">46</span>(1175):10–1.</span> [<a href="/pubmed/14749610" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14749610</span></a>]<div><i>(Concise review of the efficacy, safety and costs of the over-the-counter form of Plan B that contains two 0.75 mg tablets of levonorgestrel; mentions side effects of nausea and vomiting, headache, abdominal pain and breast tenderness).</i></div></div></li><li><div class="bk_ref" id="EmergencyContracepti.REF.glasier.2010.555">Glasier AF, Cameron ST, Fine PM, Logan SJ, Casale W, Van Horn J, Sogor L, et al.  Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. <span><span class="ref-journal">Lancet. </span>2010;<span class="ref-vol">375</span>(9714):555–62.</span> [<a href="/pubmed/20116841" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20116841</span></a>]<div><i>(Among 1899 women requesting emergency contraception within 5 days of unprotected sexual intercourse who were treated with either ulipristal [30 mg] or levonorgestrel [1.5 mg] and had adequate follow up evaluations, 50 pregnancies occurred and rates were lower with ulipristal [1.8% vs 2.6%] and adverse events were similar in both groups; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="EmergencyContracepti.REF6">Ella: a new emergency contraceptive. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2011;<span class="ref-vol">53</span>(1355):3–4.</span> [<a href="/pubmed/21212744" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21212744</span></a>]<div><i>(Concise review of the mechanism of action, clinical efficacy, safety, and costs of ulipristal acetate as emergency contraception shortly after its approval for use in the US; mentions its side effects of headache, nausea, abdominal pain, dysmenorrhea, fatigue, and dizziness, but not serious adverse events, ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="EmergencyContracepti.REF.snow.2011.780">Snow SE, Melillo SN, Jarvis CI. Ulipristal acetate for emergency contraception. <span><span class="ref-journal">Ann Pharmacother. </span>2011;<span class="ref-vol">45</span>:780–6.</span> [<a href="/pubmed/21666089" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21666089</span></a>]<div><i>(Review of the safety and efficacy of ulipristal for emergency contraception; mentions that common adverse events included headache [17%], breast tenderness [16%], nausea [15%] and abdominal pain [13%], and that severe adverse events were rare and none were considered related to ulipristal).</i></div></div></li><li><div class="bk_ref" id="EmergencyContracepti.REF.chen.2011.2316">Chen QJ, Xiang WP, Zhang DK, Wang RP, Luo YF, Kang JZ, Cheng LN. Efficacy and safety of a levonorgestrel enteric-coated tablet as an over-the-counter drug for emergency contraception: a Phase IV clinical trial. <span><span class="ref-journal">Hum Reprod. </span>2011;<span class="ref-vol">26</span>:2316–21.</span> [<a href="/pmc/articles/PMC3157624/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3157624</span></a>] [<a href="/pubmed/21672924" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21672924</span></a>]<div><i>(Among 2445 women requesting emergency contraception treated with levonorgestrel within 72 hours of unprotected intercourse, the pregnancy rate was 0.2% and adverse events included nausea, vomiting, vaginal bleeding, headache, and dizziness, but there was no mention of ALT elevations or liver related adverse events).</i></div></div></li><li><div class="bk_ref" id="EmergencyContracepti.REF.cheng.2012.cd001324">Cheng L, Che Y, G&#x000fc;lmezoglu AM. Interventions for emergency contraception. <span><span class="ref-journal">Cochrane Database Syst Rev. </span>2012;(8):CD001324. </span> [<a href="/pubmed/22895920" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22895920</span></a>]<div><i>(Systematic analysis of 100 randomized controlled trials of emergency contraception with 55,666 women using mifepristone, levonorgestrel, copper intrauterine device placement and ulipristal, reported that all regimens were safe; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="EmergencyContracepti.REF.donnez.2012.409">Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, Ugocsai G, et al.  PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. <span><span class="ref-journal">N Engl J Med. </span>2012;<span class="ref-vol">366</span>:409–20.</span> [<a href="/pubmed/22296075" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22296075</span></a>]<div><i>(Among 239 women with symptomatic uterine fibroids and excessive bleeding treated with ulipristal [5 vs 10 mg] or placebo daily for up to 13 weeks before surgery, uterine bleeding and fibroid size decreased with ulipristal and adverse events included amenorrhea [73% and 82% vs 6%], headache and breast pain, but &#x0201c;there was no significant difference among the groups in the incidence of abnormal liver-function tests&#x0201d;).</i></div></div></li><li><div class="bk_ref" id="EmergencyContracepti.REF.richardson.2012.24">Richardson AR, Maltz FN. Ulipristal acetate: review of the efficacy and safety of a newly approved agent for emergency contraception. <span><span class="ref-journal">Clin Ther. </span>2012;<span class="ref-vol">34</span>:24–36.</span> [<a href="/pubmed/22154199" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22154199</span></a>]<div><i>(Systematic review of safety and efficacy of emergency contraception using ulipristal or levonorgestrel reported no &#x0201c;clinically significant changes in biochemical parameters&#x0201d;).</i></div></div></li><li><div class="bk_ref" id="EmergencyContracepti.REF12">Plan B one-step OTC. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2013;<span class="ref-vol">55</span>(1419):52.</span> [<a href="/pubmed/23797799" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23797799</span></a>]<div><i>(Concise review of efficacy and safety of single vs two dose levonorgestrel regimens for emergency contraception; mentions common adverse events of headache, abdominal pain and breast tenderness, but does not mention ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="EmergencyContracepti.REF.turok.2014.222">Turok DK, Jacobson JC, Dermish AI, Simonsen SE, Gurtcheff S, McFadden M, Murphy PA. Emergency contraception with a copper IUD or oral levonorgestrel: an observational study of 1-year pregnancy rates. <span><span class="ref-journal">Contraception. </span>2014;<span class="ref-vol">89</span>:222–8.</span> [<a href="/pmc/articles/PMC4076674/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4076674</span></a>] [<a href="/pubmed/24332433" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24332433</span></a>]<div><i>(Among 542 women requesting emergency contraception who were treated with oral levonorgestrel or implantation of a copper IUD, the one year pregnancy rates were 12% vs 7% and there were no reports of serious adverse events, ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="EmergencyContracepti.REF.levy.2014.431">Levy DP, Jager M, Kapp N, Abitbol JL. Ulipristal acetate for emergency contraception: postmarketing experience after use by more than 1 million women. <span><span class="ref-journal">Contraception. </span>2014;<span class="ref-vol">89</span>:431–3.</span> [<a href="/pubmed/24508124" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24508124</span></a>]<div><i>(A summary of spontaneous reports of adverse events after use of ulipristal for emergency contraception in more than one million women mentions side effects of nausea, headache, abdominal pain, and dizziness, but not ALT elevations or liver related adverse events).</i></div></div></li><li><div class="bk_ref" id="EmergencyContracepti.REF.cleland.2014.741">Cleland K, Raymond EG, Westley E, Trussell J. Emergency contraception review: evidence-based recommendations for clinicians. <span><span class="ref-journal">Clin Obstet Gynecol. </span>2014;<span class="ref-vol">57</span>:741–50.</span> [<a href="/pmc/articles/PMC4216625/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4216625</span></a>] [<a href="/pubmed/25254919" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25254919</span></a>]<div><i>(Review of emergency contraception mentions that the failure rates of ulipristal range from 0.9-2.1% and of levonorgestrel 0.6-3.1%, although both are less effective when given as an advance supply; in addition, they &#x0201c;have an excellent safety profile, and no deaths or serious complications have been causally linked&#x0201d; to their use).</i></div></div></li><li><div class="bk_ref" id="EmergencyContracepti.REF.donnez.2015.519">Donnez J, Hudecek R, Donnez O, Matule D, Arhendt HJ, Zatik J, Kasilovskiene Z, et al.  Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. <span><span class="ref-journal">Fertil Steril. </span>2015;<span class="ref-vol">103</span>:519–27.e3.</span> [<a href="/pubmed/25542821" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25542821</span></a>]<div><i>(Among 451 patients with symptomatic uterine fibroids treated with two 12-week courses of ulipristal [5 vs 10 mg daily], more than 80% had control of bleeding, and &#x0201c;laboratory results did not reveal any safety signals, and no patients discontinued treatment due to test abnormalities&#x0201d;).</i></div></div></li><li><div class="bk_ref" id="EmergencyContracepti.REF.chalasani.2015.1340">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al. United States Drug Induced Liver Injury Network.  Features and outcomes of 899 patients with drug-induced liver injury: the DILIN Prospective Study. <span><span class="ref-journal">Gastroenterology. </span>2015;<span class="ref-vol">148</span>:1340–52.e7.</span> [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury in the US collected between 2004 and 2012, no cases were attributed to emergency contraception regimens).</i></div></div></li><li><div class="bk_ref" id="EmergencyContracepti.REF.festin.2016.530">Festin MP, Bahamondes L, Nguyen TM, Habib N, Thamkhantho M, Singh K, Gosavi A, et al.  A prospective, open-label, single arm, multicentre study to evaluate efficacy, safety and acceptability of pericoital oral contraception using levonorgestrel 1.5 mg. <span><span class="ref-journal">Hum Reprod. </span>2016;<span class="ref-vol">31</span>:530–40.</span> [<a href="/pmc/articles/PMC4755445/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4755445</span></a>] [<a href="/pubmed/26830816" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26830816</span></a>]<div><i>(Among 330 women at risk of pregnancy given levonorgestrel tablets [1.5 mg] to use within 24 hours of intercourse, the pregnancy rate was 7.5 per 100 years of use and there were 3 serious adverse events [choledocholithiasis, anemia, and rupture of a corpus luteum cyst]; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="EmergencyContracepti.REF.fauser.2017.e0173523">Fauser BC, Donnez J, Bouchard P, Barlow DH, V&#x000e1;zquez F, Arriagada P, Skouby SO, et al.  Safety after extended repeated use of ulipristal acetate for uterine fibroids. <span><span class="ref-journal">PLoS One. </span>2017;<span class="ref-vol">12</span>:e0173523. </span> [<a href="/pmc/articles/PMC5340384/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5340384</span></a>] [<a href="/pubmed/28267814" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28267814</span></a>]<div><i>(Among 64 women with uterine fibroids treated with 1 to 8 three-month courses of ulipristal [10 mg daily], there were no changes in mean ALT or AST levels or in the &#x0201c;number of laboratory results falling outside of the normal range&#x0201d;).</i></div></div></li><li><div class="bk_ref" id="EmergencyContracepti.REF.rabe.2018.1374821">Rabe T, Saenger N, Ebert AD, Roemer T, Tinneberg HR, De Wilde RL, Wallwiener M. Selective progesterone receptor modulators for the medical treatment of uterine fibroids with a focus on ulipristal acetate. <span><span class="ref-journal">Biomed Res Int. </span>2018;<span class="ref-vol">2018</span>:1374821. </span> [<a href="/pmc/articles/PMC6261240/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6261240</span></a>] [<a href="/pubmed/30539001" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30539001</span></a>]<div><i>(Review of the efficacy and safety of ulipristal as therapy of uterine fibroids).</i></div></div></li><li><div class="bk_ref" id="EmergencyContracepti.REF.donnez.2018.593">Donnez J. Liver injury and ulipristal acetate: an overstated tragedy? <span><span class="ref-journal">Fertil Steril. </span>2018;<span class="ref-vol">110</span>:593–5.</span> [<a href="/pubmed/30196943" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30196943</span></a>]<div><i>(Brief summary of the results of liver test monitoring in the preregistration trials of ulipristal which showed no signal for potential hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="EmergencyContracepti.REF22">Ulipristal acetate (Esmya): restrictions on use. <span><span class="ref-journal">Drug Ther Bull. </span>2018;<span class="ref-vol">56</span>:127.</span> [<a href="/pubmed/30297449" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30297449</span></a>]<div><i>(Summary of a European Union wide review of ulipristal that was initiated after receipt of 8 reports of severe liver injury among an estimated 750,000 women treated with the agent for uterine fibroids, which resulted in recommendations to restrict use of ulipristal [to women with normal liver tests and who have refractory, moderate-to-severe, symptomatic fibroids] and require monitoring of liver tests before, during and after each course of therapy).</i></div></div></li><li><div class="bk_ref" id="EmergencyContracepti.REF.donnez.2018.1225">Donnez J, Arriagada P, Marciniak M, Larrey D. Liver safety parameters ofulipristal acetate for the treatment of uterine fibroids: a comprehensive review of the clinical development program. <span><span class="ref-journal">Expert Opin Drug Saf. </span>2018;<span class="ref-vol">17</span>:1225–32.</span> [<a href="/pubmed/30460871" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30460871</span></a>]<div><i>(Detailed analysis of the changes in serum ALT, AST, Alk P and bilirubin levels in the preregistration trials of ulipristal during which there were no elevations in ALT above 3 times ULN among 422 women who received 5 mg daily and only 7 of 631 who received 10 mg daily, and no instance of clinically apparent liver injury at any dosage).</i></div></div></li><li><div class="bk_ref" id="EmergencyContracepti.REF.donnez.2019.27">Donnez J, Courtoy GE, Dolmans MM. Fibroid management in premenopausal women. <span><span class="ref-journal">Climacteric. </span>2019;<span class="ref-vol">22</span>:27–33.</span> [<a href="/pubmed/30601065" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30601065</span></a>]<div><i>(Review of clinical features and management of uterine fibroids in premenopausal women mentions that ulipristal &#x0201c;is safe, provides fast control of bleedings, and causes sustained fibroid volume reduction in the vast majority of cases&#x0201d;).</i></div></div></li><li><div class="bk_ref" id="EmergencyContracepti.REF.del_forno.2020.445">Del Forno S, Degli Esposti E, Salucci P, Leonardi D, Iodice R, Arena A, Raimondo D, et al.  Liver function, tolerability and satisfaction during treatment with ulipristal acetate in women with fibroids: a single center experience. <span><span class="ref-journal">Gynecol Endocrinol. </span>2020;<span class="ref-vol">36</span>:445–7.</span> [<a href="/pubmed/31646908" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31646908</span></a>]<div><i>(Among 162 women treated with at least one 3-month course of ulipristal [5 mg daily] for uterine fibroids, &#x0201c;no cases of increased serum AST or ALT levels were detected&#x0201d;).</i></div></div></li><li><div class="bk_ref" id="EmergencyContracepti.REF.meunier.2020">Meunier L, Meszaros M, Pageaux GP, Delay JM, Herrero A, Pinzani V, Dominique HB. Acute liver failure requiring transplantation caused by ulipristal acetate. Clin Res Hepatol Gastroenterol 2020: S2210-7401(20)30041-3. [<a href="/pubmed/32146092" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 32146092</span></a>]<div><i>(58 year old woman with uterine fibroids developed fatigue 2 months after starting ulipristal followed by jaundice a week after stopping [bilirubin 25.5 mg/dL, ALT 1652 U/L, GGT 252 U/L, INR 2.5], with progressive hepatic failure leading to urgent liver transplantation; publication includes a table summarizing clinical features of 3 other cases of acute liver failure and liver transplantation in women arising 1-6 months after starting ulipristal for uterine fibroids).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548051</span><span class="label">PMID: <a href="/pubmed/31643382" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643382</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Emapalumab/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Emicizumab/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548051&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548051/?report=reader">PubReader</a></li><li><a href="/books/NBK548051/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548051" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548051" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Emergency Contraceptive Agents. [Updated 2020 Jun 2].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548051/pdf/Bookshelf_NBK548051.pdf">PDF version of this page</a> (121K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=Emergency+Contraceptive+Agents/AE+AND+Human%5BMH%5D+AND+(jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI+OR+hepatitis,+toxic%5BMH%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Emergency Contraceptive Agents: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Levonorgestrel" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Levonorgestrel: from ClinicalTrials.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Ulipristal" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Ulipristal Acetate: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4857692" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4857692" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4857692" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/7956209" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Emergency contraception: a review.</a><span class="source">[Contraception. 1994]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Emergency contraception: a review.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Haspels AA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Contraception. 1994 Aug; 50(2):101-8. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/12268772" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Contraception for the older woman.</a><span class="source">[J Obstet Gynaecol (Lahore). 1985]</span><div class="brieflinkpop offscreen_noflow">Contraception for the older woman.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Guillebaud J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Obstet Gynaecol (Lahore). 1985 Jan; 5 Suppl 2:S70-7. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/1954724" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Contraception for women with diabetes: an update.</a><span class="source">[Baillieres Clin Obstet Gynaeco...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Contraception for women with diabetes: an update.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Skouby SO, Mølsted-Pedersen L, Petersen KR. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Baillieres Clin Obstet Gynaecol. 1991 Jun; 5(2):493-503. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/12319047" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Contraception after unprotected sex.</a><span class="source">[Netw Res Triangle Park N C. 1994]</span><div class="brieflinkpop offscreen_noflow">Contraception after unprotected sex.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Blaney CL. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Netw Res Triangle Park N C. 1994 Dec; 15(2):4-8. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/3102162" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.</a><span class="source">[Contraception. 1986]</span><div class="brieflinkpop offscreen_noflow">The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Smith SK, Kirkman RJ, Arce BB, McNeilly AS, Loudon NB, Baird DT. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Contraception. 1986 Nov; 34(5):513-22. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643382" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643382" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class="&#10;                        HTOn&#10;                    "><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T14:54:30-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal105&amp;ncbi_phid=CE8C34460465EBA10000000007720205&amp;ncbi_session=CE8C344604680F41_1906SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548051%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548051&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548051/&amp;ncbi_pagename=Emergency Contraceptive Agents - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C344604680F41_1906SID /projects/books/PBooks@9.2 portal105 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>